Topics

Latest "Which patients with type diabetes mellitus perceived difficult" News Stories

12:49 EST 15th November 2019 | BioPortfolio

Here are the most relevant search results for "Which patients with type diabetes mellitus perceived difficult" found in our extensive news archives from over 250 global news sources.

More Information about Which patients with type diabetes mellitus perceived difficult on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Which patients with type diabetes mellitus perceived difficult for you to read. Along with our medical data and news we also list Which patients with type diabetes mellitus perceived difficult Clinical Trials, which are updated daily. BioPortfolio also has a large database of Which patients with type diabetes mellitus perceived difficult Companies for you to search.

Showing "Which patients with type diabetes mellitus perceived difficult" News Articles 1–25 of 32,000+

Friday 15th November 2019

2019 Pemphigus Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Pemphigus Clinical Trials Study provides complete list of trials completed, ongoing and planned for Pemphigus. It presents indepth analysis of Pemphigus clinical trials across markets and companies. The research work is for providing complete understanding into trends in Pemphigus. The report covers a key snapshot of trial trends, enrollment trends, success t...


2019 Glycogen Storage Disorders Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Glycogen Storage Disorders Clinical Trials Study provides complete list of trials completed, ongoing and planned for Glycogen Storage Disorders. It presents indepth analysis of Glycogen Storage Disorders clinical trials across markets and companies. The research work is for providing complete understanding into trends in Glycogen Storage Disorders. The report...

2019 Anthrax Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Anthrax Clinical Trials Study provides complete list of trials completed, ongoing and planned for Anthrax. It presents indepth analysis of Anthrax clinical trials across markets and companies. The research work is for providing complete understanding into trends in Anthrax. The report covers a key snapshot of trial trends, enrollment trends, success trends, l...


Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

#Pancreaticcancer may go undetected until it has spread and become metastatic. At this late stage, it is more difficult to treat. Early diagnosis is essential for improving patient outcomes in pancreatic cancer. #PancreaticCancerAwarenessMonthpic.twitter.

#Pancreaticcancer may go undetected until it has spread and become metastatic. At this late stage, it is more difficult to treat. Early diagnosis is essential for improving patient outcomes in pancreatic cancer. #PancreaticCancerAwarenessMonth pic.twitter.com/Ys06gyXT9r

FDA Grants Accelerated Approval to BeiGene’s Brukinsa for Treatment of Mantle Cell Lymphoma Patients who Received at Least One Prior Therapy

CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that BRUKINSA™ (zanubrutinib) has received accelerated approval from the United States Fo...

New report reveals shocking knowledge gaps around type 2 #diabetes risk factors http://bit.ly/2QjZgrc  #pharmapic.twitter.com/pDVYotmSbC

New report reveals shocking knowledge gaps around type 2 #diabetes risk factors http://bit.ly/2QjZgrc  #pharma pic.twitter.com/pDVYotmSbC

FDA Approves Fetroja for Treatment of Complicated Urinary Tract Infections in Adults with Limited or No Alternative Treatments

OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced the U.S. Food and Drug Administration (FDA) has approved FETROJA® (cefiderocol) for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, ...

Today, we joined @CRUKresearch for the opening of the Functional Genomics Centre in #Cambridge. Through our collaboration, we aim to deepen understanding of cancer biology and accelerate development of treatments for patients with #cancer. Full video here

Today, we joined @CRUKresearch for the opening of the Functional Genomics Centre in #Cambridge. Through our collaboration, we aim to deepen understanding of cancer biology and accelerate development of treatments for patients with #cancer. Full video here: http://bit.ly/2pq3P8w 

2019 Genital Warts Condylomata Acuminata Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Genital Warts Condylomata Acuminata Clinical Trials Study provides complete list of trials completed, ongoing and planned for Genital Warts Condylomata Acuminata. It presents indepth analysis of Genital Warts Condylomata Acuminata clinical trials across markets and companies. The research work is for providing complete understanding into trends in Genital War...

Unlike Fine Wine, Shoulder Joints Don’t Get Better with Age

Hand and Upper Limb Orthopedic Surgeon Dr. Alejandro Badia Discusses Shoulder Impingement, Rotator Cuff Disease; Offers Tips for Reducing Risk of Shoulder Joint disorders. MIAMI (PRWEB) November 15, 2019 Unlike fine wine, shoulder joints do not get better with age. Risks for developing shoulder problems – most notably, shoulder impingement syndrome and rotator cuff disease – rise after age 50...

2019 Focal Segmental Glomerulosclerosis FSGS Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Focal Segmental Glomerulosclerosis FSGS Clinical Trials Study provides complete list of trials completed, ongoing and planned for Focal Segmental Glomerulosclerosis FSGS. It presents indepth analysis of Focal Segmental Glomerulosclerosis FSGS clinical trials across markets and companies. The research work is for providing complete understanding into trends in...

STAT Plus: Pharmalittle: Senators propose a new agency to control drug costs; FDA panel backs Amarin fish-oil pill

An FDA advisory committee voted 16-to-0 in favor of expanded use of a fish-oil-derived drug from Amarin to reduce the likelihood of heart attacks and strokes in high-risk patients.

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals

The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately im...

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites and sponsors with their new integration

Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax, with ActiGraph’s CentrePoint system. The integration, which The post Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites and sponsors with their new integration appeared first on NS Medical Devices.

Heat Biologics, Inc.: Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

Reported Positive Phase 2 Interim Data in Advanced Non-Small Cell Lung Cancer Patients MORRISVILLE, NC / ACCESSWIRE / November 15, 2019 / Heat Biologics, Inc. (Nasdaq:HTBX), a biopharmaceutical com...

X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that management will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19th, 2019 at 8:35 am EST in New York, NY. About X4 Pharmaceuticals X4 Pharmaceuticals is developing novel therapeutics...

Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program

OPC1 Overall Safety Profile Excellent with Motor Recovery Gains in Upper Extremities Maintained Through Year 2 Follow-Ups Available to Date OPC1 Manufacturing Fully Transferred to cGMP Facility; Improvements to Manufacturing Process Planned During 2020 FDA Meeting to Discuss OPC1 Manufacturing and Clinical Development Planned for Mid-2020 Lineage Cell Therapeutics, Inc. (NYSE American and ...

Fractyl Announces New Data from Revita-1 Clinical Study Showing Durable Benefits after a Single Treatment Through Two Years of Follow Up

Fractyl Laboratories Inc. (Fractyl) today announced that the company will present positive results from the long-term follow-up from the Revita-1 study2 at the Diabetes Technology Meeting taking place in Bethesda, Md. The data shows that patients experienced a 1% reduction in HbA1c (from a baseline HbA1c of 8.5% to 7.5%; n=34; p < 0.01) through 24 months of follow-up from a single outpatient R...

Shionogi'gains US approval in complicated urinary tract infections with Fetroja

Shionogi’s antibacterial therapy Fetroja (cefiderocol) has secured approval in the US for the treatment of complicated urinary tract infections (cUTI), it has emerged. The approval relates specifically to adult patients with cUTI’s including kidney infections caused by susceptible Gram-negative microorganisms who have limited or no alternative treatment options. The ruling was made under the Q...

Treatment could be delivered to stroke patients via tiny transporters

Scientists have discovered that liposomes can translocate through the blood brain barrier following stroke and may be able to get drugs to the lesions to stop further damage. The post

ResTORbio's respiratory illness drug fails late-stage study

ResTORbio Inc's said on Friday its lead drug missed the main goal in a late-stage testing in patients aged above 65 with respiratory illness.

Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous treatment The positive opinion was based on the results of the Phase 3 AUGMENT study, which showed the R2 regimen conferred a statistically significantly improvement in progression-free survival versus r...

Label expansion of Amarin's Vascepa has unanimous backing of FDA advisory panel

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding the existing approval of Irish firm Amarin’s Vascepa (icosapent ethyl) to cover the the reduction of cardiovascular events in high-risk patients. The advisory panel voted unanimously in favour of the motion – all 16 votes for – presenting a compelling argument for the US agency when it ...

What Do Clinicians Need to Know About LTC Insurance?

Private long-term care insurance can help aging patients prepare for future care needs. Find out what there is to know. Journal of the American Geriatrics Society


Quick Search

News Quicklinks